Location:  Jackson, TN; Orlando, FL

Indication:  Atopic Dermatitis and Healthy Controls

Sponsor: Precision Biospecimen Solutions, Inc.

PI: Dafnis Carranza, MD; Christopher Chappel, MD

Intervention/Treatment: Biospecimen collection

Ages: 18+


  • Subjects with a documented diagnosis of Atopic Dermatitis
    • Diagnosis must be within one year
  • Healthy subjects without a diagnosis of Atopic Dermatitis or generalized dermatology conditions

Compensation: You may be compensated for your time and participation

Location: Jackson, TN

Indication: Plaque Psoriasis

Sponsor: Nimbus Lakshmi, Inc.

PI: Dafnis Carranza, MD

Intervention/Treatment: NDI-034858 (Oral)

Ages: 18-70

• Must have a history of plaque psoriasis for at least 6 months
• Must have moderate to severe plaque psoriasis
• Must have NO significant flare is psoriasis for at least 3 months
• Must NOT have a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessment
• Must NOT be breastfeeding, pregnant or planning to become pregnant

Compensation: You may be compensated for your time and participation.

About: The study is designed to evaluate the efficacy, safety and tolerability of NDI-034858 in subjects with moderate to severe plaque psoriasis. The study will evaluate the plasma concentrations of the drug and explore the immune response to NDI-034858 in subjects.
The subject will come to the site on 8 occasions. During the treatment period, the medication or placebo will be taken orally every day for 12 weeks. The 12-week treatment period will be followed by a 4-week safety follow-up period.

Location: Orlando, FL

Indication: Urticaria

Sponsor: Teva Pharmaceuticals USA

PI: Christopher Chappel, MD

Intervention/Treatment: TEV-45779 and XOLAIR®️️️

Age: 18-75

• Has diagnosis of CIU refractory to H1 antihistamines for ≥3 months
• Does NOT have chronic urticaria with clearly defined underlying etiology
• Does NOT have other skin disease associated with itch

Compensation: You may be compensated for your time and participation

About: The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.

Start typing and press Enter to search